Exinity ME Limited (https://nemo.money) is licensed by Abu Dhabi Global Market (ADGM) and regulated by ADGM's Financial Services Regulatory Authority (FSRA) as an Authorised Person to conduct the Regulated Activities of (a) Dealing in Investments as Principal (Matched), (b) Dealing in Investments as Agent, and (c) Arranging Custody, in and from ADGM, with Financial Services Permission No. 200015. Its registered office is 16-104, 16th Floor, Al Khatem Tower, ADGM Square, Al Maryah Island, Abu Dhabi, UAE.

Exinity ME Limited, trading as Nemo, is part of the Exinity Group, which includes but is not limited to:

Exinity UK Limited with registration number 10599136 and registration address at 8-10 Old Jewry, London, England, EC2R 8DN is authorised and regulated by the Financial Conduct Authority with license number 777911.

Exinity Capital East Africa Ltd with registration number PVT-ZQU6JE7 and registration address at West End Towers, Waiyaki Way, 6th Floor, P.O. Box 1896-00606, Nairobi, Republic of Kenya is regulated by the Capital Markets Authority of the Republic of Kenya with a Non-Dealing Online Foreign Exchange Broker with license number 135.

Risk Warning: You should not invest more than you can afford to lose and should ensure that you fully understand the risks involved. It is the responsibility of the client to ascertain whether he/she is permitted to use the services of Exinity ME Ltd based on the legal requirements in his/her country of residence.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Please read Nemo's full Risk Disclosure.

For Q2 2026, 30% of Retail Client accounts that traded or held OTC Leveraged CFDs were profitable. For Q1 2026, 28.7% were profitable. For Q4 2025, 41% were profitable. For Q3 2025, 52% were profitable.

Disclaimer: This written/visual material is compromised by personal opinions and ideas. The content should not be construed as containing any type of investment recommendation and/or a solicitation for any transactions. It does not imply any obligation to purchase investment services, nor does it guarantee or predict future performance. Exinity ME Ltd, its affiliates, agents, directors, officers or employees do not guarantee the accuracy, validity, timeliness or completeness of any information or data made available and assume no liability for any loss arising from any investment based on the same.

Terms & Conditions

Themes Insights Stocks Compare

Themes Insights Stocks Compare

Plus Therapeutics (PSTV) Stock: Price, Analysis & 2026 Outlook

PLUS THERAPEUTICS INC

Plus Therapeutics (PSTV) Stock

Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Plus Therapeutics in September 2026.

≈

Sixth Month Growth Performance

$3.87

+0.77 (24.84%)past 6 months

About This Stock

PLUS THERAPEUTICS INC

PSTV

Current Price

$3.87

Potential 12 Month Profit

749.18%

Sector

N/A

Industry

N/A

Ticker

PSTV

Market Cap

$24.99M

Potential 12 Month Profit

749.18%

Sector

N/A

Industry

N/A

Why invest with Nemo?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend purchasing Plus Therapeutics' stock with a target price of $31.25, indicating strong growth potential.

Average

Financial Health

PLUS Therapeutics has modest revenue and cash flow, indicating a stable but unspectacular financial position.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

View more stocks by downloading the app for FREE

It only takes 60 seconds.

Baskets Featuring PSTV

Radiopharma Revolution: Promise Meets Market Risk

Radiopharma Revolution: Promise Meets Market Risk

Aktis Oncology's highly successful and upsized IPO, strongly backed by pharma giant Eli Lilly, signals a surge of investor confidence in radiopharmaceutical cancer therapies. This theme focuses on the companies poised to ride this wave of investment and innovation in one of biotech's most promising frontiers.

Published: 9 January 2026